Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

November 21, 2017

Study Completion Date

March 16, 2018

Conditions
Type 2 DiabetesDyslipidemia
Interventions
DRUG

Metformin + Rosuvastatin

Group I: Metformin + Rosuvastatin,

DRUG

Metformin + placebo

Group II: Metformin + placebo,

DRUG

placebo + Rosuvastatin

Group III: placebo + Rosuvastatin

Trial Locations (33)

Unknown

Buchoen St. mary's Hospital, Bucheon-si

SeJong Hostpital, Bucheon-si

SoonChunHyang University Bucheon Hospital, Bucheon-si

InJe University Busan paik Hospital, Busan

Inje University Haeundae paik hospital, Busan

Daegu Catholic University Medical Center, Daegu

Youngnam University Hostpital, Daegu

Daeheon Eulji Medical Center, Daejeon

KonYang University Hostpital, Daejeon

Chosun University Hospital, Gwangju

BunDang Jesang Hospital(DMC), Gyeonggi-do

Hallym University Sacred Heart hospital, Gyeonggi-do

HanYang University Guri Hospital, Gyeonggi-do

Inje University Ilsan paik hospital, Gyeonggi-do

Myoung Ji Hospital, Gyeonggi-do

Gachon Gil Hospital, Incheon

Inchoen St. mary's Hospital, Incheon

Eulji Hospital Nowon, Seoul

Hallym University Kangnam Sacred Heart hospital, Seoul

KangBuk SamSung Hospital, Seoul

Kangdong Sacred Heart Hospital, Seoul

KonKuk University Medical Center, Seoul

Korea University Anam Hospital, Seoul

KyungHee University Hospital at Gangdong, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital(Famlily medicine), Seoul

Seoul National University Hospital, Seoul

Severance hospital, Seoul

SoonChunHayng University Hospital Seoul, Seoul

The catholic University of Korea YEOUIDO St mary's Hospital, Seoul

Korea University Guro hospital, Soeul

Ajou University hospital, Suwon

Wonju Severance Christian hospital, Wŏnju

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT02827903 - Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia | Biotech Hunter | Biotech Hunter